​

Bausch Health Companies (BHC) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BHC Stock Forecast

Bausch Health Companies (BHC) stock forecast, based on 38 Wall Street analysts, predicts a 12-month average price target of $8.00, with a high of $8.00 and a low of $8.00. This represents a 17.30% increase from the last price of $6.82.

$5 $6 $7 $8 $9 $10 $11 High: $8 Avg: $8 Low: $8 Last Closed Price: $6.82

BHC Stock Rating

Bausch Health Companies stock's rating consensus is Buy, based on 38 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 20 Buy (52.63%), 14 Hold (36.84%), 4 Sell (10.53%), and 0 Strong Sell (0.00%).

Buy
Total 38 0 4 14 20 Strong Sell Sell Hold Buy Strong Buy

BHC Price Target Upside V Benchmarks

TypeNameUpside
StockBausch Health Companies17.30%
SectorHealthcare Stocks 15.45%
IndustrySpecialty & Generic Drug Manufacturers Stocks19.92%

Price Target Trends

1M3M12M
# Anlaysts111
Avg Price Target$8.00$8.00$8.00
Last Closing Price$6.82$6.82$6.82
Upside/Downside17.30%17.30%17.30%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 251-5-17
Nov, 251-5-17
Oct, 251-5-17
Sep, 251-5-17
Aug, 251-5-17
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 08, 2025Glen SantangeloBarclays$8.00$6.8217.30%17.30%
Oct 23, 2024Douglas MiehmRBC Capital$10.00$8.0723.92%46.63%
Jul 25, 2024Les SulewskiTruist Financial$7.00$5.6923.02%2.64%
Jul 10, 2024Michael FreemanRaymond James$8.00$7.1911.27%17.30%
Apr 29, 2024David AmsellemPiper Sandler$9.00$8.782.51%31.96%
Apr 23, 2024Doug MiehmRBC Capital$11.00$8.4530.18%61.29%
Apr 11, 2024Glen SantangeloJefferies$16.00$9.2872.41%134.60%
Apr 05, 2024Doug MiehmRBC Capital$12.00$10.0519.40%75.95%
Sep 09, 2022Piper Sandler$6.00$6.70-10.45%-12.02%
Jul 26, 2022RBC Capital$12.00$8.7437.30%75.95%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Dec 08, 2025BarclaysNeutralinitialise
Oct 23, 2024RBC CapitalSector PerformSector Performhold
Aug 01, 2024Piper SandlerNeutralUnderweightdowngrade
Jul 10, 2024Raymond JamesMarket Performinitialise
Apr 29, 2024Piper SandlerNeutralNeutralhold
Apr 08, 2024Cowen & Co.HoldHoldhold
Apr 05, 2024RBC CapitalSector PerformSector Performhold
Mar 28, 2024JefferiesBuyBuyhold
Feb 23, 2024RBC CapitalSector PerformSector Performhold
Sep 09, 2022Piper SandlerNeutralNeutralhold

Financial Forecast

EPS Forecast

$-3 $-2 $-1 $0 $1 $2 $3 $4 $5 $6 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.57$-2.61$-0.59$-1.62$1.10----
Avg Forecast$3.75$4.21$2.97$3.46$3.68$4.13$4.68$4.98$3.54
High Forecast$3.81$4.28$3.02$3.60$3.94$4.57$4.79$5.09$3.62
Low Forecast$3.68$4.13$2.90$3.42$3.50$3.20$4.54$4.83$3.43
Surprise %-141.87%-162.00%-119.87%-146.82%-70.11%----

Revenue Forecast

$8B $8B $9B $9B $10B $11B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$8.03B$8.43B$8.12B$8.76B$9.52B----
Avg Forecast$8.00B$8.39B$8.05B$8.81B$9.43B$9.67B$9.95B$10.22B$9.13B
High Forecast$8.11B$8.50B$8.16B$8.86B$9.49B$9.82B$10.14B$10.42B$9.29B
Low Forecast$7.88B$8.27B$7.90B$8.76B$9.40B$9.51B$9.75B$10.02B$8.92B
Surprise %0.33%0.51%0.97%-0.55%0.98%----

Net Income Forecast

$-2B $-800M $-100M $600M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-559.00M$-937.00M$-212.00M$-592.00M$-46.00M----
Avg Forecast$-649.22M$-899.13M$-477.55M$-592.00M$1.36B$1.42B$1.70B$1.82B$1.29B
High Forecast$-498.62M$-625.37M$-278.71M$-345.51M$1.44B$1.67B$1.75B$1.86B$1.32B
Low Forecast$-799.81M$-1.17B$-676.40M$-838.49M$1.28B$1.17B$1.66B$1.76B$1.25B
Surprise %-13.90%4.21%-55.61%--103.39%----

BHC Forecast FAQ

Is Bausch Health Companies stock a buy?

Bausch Health Companies stock has a consensus rating of Buy, based on 38 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 20 Buy, 14 Hold, 4 Sell, and 0 Strong Sell, reflecting a consensus that Bausch Health Companies is a favorable investment for most analysts.

What is Bausch Health Companies's price target?

Bausch Health Companies's price target, set by 38 Wall Street analysts, averages $8 over the next 12 months. The price target range spans from $8 at the low end to $8 at the high end, suggesting a potential 17.30% change from the previous closing price of $6.82.

How does Bausch Health Companies stock forecast compare to its benchmarks?

Bausch Health Companies's stock forecast shows a 17.30% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the specialty & generic drug manufacturers stocks industry (19.92%).

What is the breakdown of analyst ratings for Bausch Health Companies over the past three months?

  • December 2025: 14.29% Strong Buy, 0% Buy, 71.43% Hold, 0% Sell, 14.29% Strong Sell.
  • November 2025: 14.29% Strong Buy, 0% Buy, 71.43% Hold, 0% Sell, 14.29% Strong Sell.
  • October 2025: 14.29% Strong Buy, 0% Buy, 71.43% Hold, 0% Sell, 14.29% Strong Sell.

What is Bausch Health Companies’s EPS forecast?

Bausch Health Companies's average annual EPS forecast for its fiscal year ending in December 2025 is $4.13, marking a 275.45% increase from the reported $1.1 in 2024. Estimates for the following years are $4.68 in 2026, $4.98 in 2027, and $3.54 in 2028.

What is Bausch Health Companies’s revenue forecast?

Bausch Health Companies's average annual revenue forecast for its fiscal year ending in December 2025 is $9.67B, reflecting a 1.58% increase from the reported $9.52B in 2024. The forecast for 2026 is $9.95B, followed by $10.22B for 2027, and $9.13B for 2028.

What is Bausch Health Companies’s net income forecast?

Bausch Health Companies's net income forecast for the fiscal year ending in December 2025 stands at $1.42B, representing a -3184.23% decrease from the reported $-46M in 2024. Projections indicate $1.7B in 2026, $1.82B in 2027, and $1.29B in 2028.